Full-Time

Director – Field Access

Confirmed live in the last 24 hours

Axsome Therapeutics Inc

Axsome Therapeutics Inc

201-500 employees

Develops therapies for CNS disorders

Biotechnology
Healthcare

Compensation Overview

$180k - $225kAnnually

+ Annual Bonus + Equity

Senior, Expert

Remote in USA

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Requirements
  • 10+ years of industry experience with a minimum of 5 years' experience in leadership roles within Market Access, Payor Account Management, and/or Access Reimbursement
  • Comprehensive knowledge of payer policy, coverage and payment processes
  • Strong knowledge of compliance guidelines and principles related to Field Reimbursement teams and both their external and internal interactions
  • Demonstrated excellence in leadership and strategic roles
  • Ability to oversee national team and key customer base, requiring travel throughout the United States when needed (30-50% travel), and use of technologies to successfully engage virtually
Responsibilities
  • Work cross functionally to develop and implement strategies for effective access pull through support across all regions and territories
  • Provide senior-level insights on national/regional payer policies, aiding the team in navigating payer issues, prior authorization pull through, and claims submission
  • High level vendor management and oversight for key vendor partners on topics related to access support and pull through
  • Analyze trends in payer behavior for approved products and strategize accordingly with internal Axsome support teams
  • Build, lead, and coach a team of Field Access Managers in their engagement with healthcare providers focused on access pull through and access education
  • Through virtual and in-person activities, build and maintain high-level relationships with key accounts and stakeholders
  • Stay ahead of significant market access, reimbursement, and policy developments
  • Ensure the team is informed about changes in healthcare laws, insurance policies, and reimbursement methodologies to provide accurate and compliant support
  • Partner with training and development team to build out a managed access and patient services curriculum and educational resources
Axsome Therapeutics Inc

Axsome Therapeutics Inc

View

Axsome Therapeutics develops therapies for central nervous system (CNS) disorders, focusing on conditions like major depressive disorder, treatment-resistant depression, and Alzheimer's agitation. Their main product, AXS-05, is an oral medication that works by blocking NMDA receptors in the brain to help regulate mood. This drug has shown positive results in clinical trials and has received FDA Breakthrough Therapy Designation, which helps speed up its approval process. Unlike many competitors, Axsome emphasizes addressing unmet medical needs in CNS disorders and aims to improve patient outcomes through rigorous research and development. The company's goal is to bring effective treatments to market, enhancing the quality of life for patients suffering from these conditions.

Company Stage

IPO

Total Funding

$430.7M

Headquarters

New York City, New York

Founded

2012

Growth & Insights
Headcount

6 month growth

3%

1 year growth

3%

2 year growth

3%
Simplify Jobs

Simplify's Take

What believers are saying

  • The launch of Auvelity and the promising results of AXS-12 in Phase 3 trials indicate strong potential for revenue growth and market impact.
  • Axsome's strategic expansion of its sales force to support Auvelity's launch demonstrates its commitment to commercial success.
  • The appointment of experienced leaders like Dr. Sue Mahony to the board enhances Axsome's strategic direction and governance.

What critics are saying

  • The biopharmaceutical sector's inherent risks, including regulatory hurdles and clinical trial failures, could impact Axsome's progress.
  • High competition in the CNS disorder treatment market may challenge Axsome's ability to capture significant market share.

What makes Axsome Therapeutics Inc unique

  • Axsome Therapeutics focuses on CNS disorders with a strong emphasis on unmet medical needs, setting it apart from broader biopharmaceutical companies.
  • The FDA Breakthrough Therapy Designation for AXS-05 highlights its innovative approach and potential for rapid market entry.
  • Axsome's diversified pipeline, including treatments for MDD, TRD, Alzheimer's agitation, and narcolepsy, showcases its comprehensive strategy in CNS therapeutics.

Help us improve and share your feedback! Did you find this helpful?